CAS 25406-64-8|Morroniside
Introduction：Basic information about CAS 25406-64-8|Morroniside, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Morroniside | ||
|---|---|---|---|
| CAS Number | 25406-64-8 | Molecular Weight | 406.382 |
| Density | 1.5±0.1 g/cm3 | Boiling Point | 635.6±55.0 °C at 760 mmHg |
| Molecular Formula | C17H26O11 | Melting Point | / |
| MSDS | / | Flash Point | 227.0±25.0 °C |
Names
| Name | methyl 3-hydroxy-1-methyl-8-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-1,3,4,4a,8,8a-hexahydropyrano[3,4-c]pyran-5-carboxylate |
|---|---|
| Synonym | More Synonyms |
Morroniside BiologicalActivity
| Description | Morroniside has neuroprotective effect by inhibiting neuron apoptosis and MMP2/9 expression. |
|---|---|
| Related Catalog | Natural Products >>Terpenoids and GlycosidesResearch Areas >>Metabolic DiseaseResearch Areas >>Neurological Disease |
| Target | MMP2 MMP9 |
| In Vivo | Morroniside reduces the expression of MMP2 and MMP9 in an I/R injury model. Treatment with Morroniside significantly reduces I/R‑associated neuron apoptosis in a dose dependent manner. The results demonstrate that active caspase‑3 and Bax are significantly upregulated in the model group compared with the control group, while Bcl‑2 is significantly downregulated. The expression of active caspase‑3 and Bax is significantly downregulated by Morroniside treatment in a dose‑dependent manner, while the expression of Bcl‑2 is significantly upregulated[1]. Morroniside has an ameliorative effect on diabetes-induced alterations such as oxidative stress, inflammation, and apoptosis in the liver of type 2 diabetic db/db mice[2]. |
| Animal Admin | Rats[1] A total of 50 adult male Sprague Dawley rats (age, 7 8 weeks; weight, 260 280 g) are used. Rats are randomly assigned into five groups (n=10 in each). Rats in the control group undergo sham surgery. All other rats undergo suture occluded surgery, with a 0.26 mm nylon monofilament inserted through the right common carotid artery and are divided into groups as follows: The cerebral I/R injury model group (model), no treatment; low dose group, 30 mg/kg/day Morroniside by gavage; moderate dose group, 90 mg/kg/day Morroniside by gavage; high dose group, 270 mg/kg/day Morroniside by gavage. Rats in the control and model groups receive an equal volume of normal saline[1]. |
| References | [1]. Zeng G, et al. Morroniside protects against cerebral ischemia/reperfusion injury by inhibiting neuron apoptosis and MMP2/9 expression. Exp Ther Med. 2018 Sep;16(3):2229-2234. [2]. Park CH, et al. Evaluation of morroniside, iridoid glycoside from Corni Fructus, on diabetes-induced alterations such as oxidative stress, inflammation, and apoptosis in the liver of type 2 diabetic db/db mice. Biol Pharm Bull. 2011;34(10):1559-65. |
Chemical & Physical Properties
| Density | 1.5±0.1 g/cm3 |
|---|---|
| Boiling Point | 635.6±55.0 °C at 760 mmHg |
| Molecular Formula | C17H26O11 |
| Molecular Weight | 406.382 |
| Flash Point | 227.0±25.0 °C |
| Exact Mass | 406.147522 |
| PSA | 164.37000 |
| LogP | -3.16 |
| Vapour Pressure | 0.0±4.2 mmHg at 25°C |
| Index of Refraction | 1.597 |
| InChIKey | YTZSBJLNMIQROD-KKORFXOPSA-N |
| SMILES | COC(=O)C1=COC(OC2OC(CO)C(O)C(O)C2O)C2C(C)OC(O)CC12 |
| Storage condition | 2-8C |
Synonyms
| N1489 |
| 1H,3H-Pyrano[3,4-c]pyran-5-carboxylic acid, 8-(β-D-glucopyranosyloxy)-4,4a,8,8a-tetrahydro-3-hydroxy-1-methyl-, methyl ester, (1S,4aS,8S,8aS)- |
| Morroniside |
| Methyl (1S,3R,4aS,8S,8aS)-8-(β-D-glucopyranosyloxy)-3-hydroxy-1-methyl-4,4a,8,8a-tetrahydro-1H,3H-pyrano[3,4-c]pyran-5-carboxylate |
| Methyl (1S,4aS,8S,8aS)-8-(β-D-glucopyranosyloxy)-3-hydroxy-1-methyl-4,4a,8,8a-tetrahydro-1H,3H-pyrano[3,4-c]pyran-5-carboxylate |
| b-Morroniside |
| 1H,3H-Pyrano[3,4-c]pyran-5-carboxylic acid, 8-(β-D-glucopyranosyloxy)-4,4a,8,8a-tetrahydro-3-hydroxy-1-methyl-, methyl ester, (1S,3R,4aS,8S,8aS)- |
| Morronisid |
| Morroniside (α+β) |
